LBP Antibody

Western blot validation of proteins overexpressed in cancer sera. (A) Western blots of 50 μg of medium and low abundance proteins from each non-cancer (N1-N6) and cancer (C1-C6) serum pool depleted by the IgY12 HPLC column were probed with the antibodies to ECM1, LBP1, and alpha-1 antitrypsin. (B) A replicate of the PVDF blot was stained for total protein with colloidal gold as a control for loading/transfer. Bracket indicates the approximate region of the blot where proteins of interest would be expected. Image collected and cropped by CiteAb from the following open publication (//proteomesci.biomedcentral.com/articles/10.1186/1477-5956-8-31), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western blot validation of proteins overexpressed in cancer sera. (A) Western blots of 50 μg of medium and low abundance proteins from each non-cancer (N1-N6) and cancer (C1-C6) serum pool depleted by the IgY12 HPLC column were probed with the antibodies to ECM1, LBP1, and alpha-1 antitrypsin. (B) A replicate of the PVDF blot was stained for total protein with colloidal gold as a control for loading/transfer. Bracket indicates the approximate region of the blot where proteins of interest would be expected. Image collected and cropped by CiteAb from the following open publication (//proteomesci.biomedcentral.com/articles/10.1186/1477-5956-8-31), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

LBP Antibody Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human LBP
  Ala26-Val481
  Accession # AAD21962
• Specificity: Detects human LBP in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse LBP is observed and less than 1% cross-reactivity with recombinant human BPI is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: LBP
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LBP Antibody

• LBP
• lipopolysaccharide binding protein
• lipopolysaccharide-binding protein
• LPS-binding protein
• MGC22233

Background

Lipopolysaccharide-binding protein (LBP), a 58 kDa glycoprotein synthesized in hepatocytes, belongs to a family of lipid-binding proteins which includes bactericidal/permeability increasing protein (BPI), phospholipid ester transfer protein (PLTP), and cholesterol ester transfer protein (CETP). LBP binds to the lipid A portion of lipopolysaccharide (LPS) to facilitate the process of LPS monomerization, catalyze the binding of LPS monomers to CD14, and promote LPS-induced immune response. LBP is present at low concentrations in normal human serum and may increase up to 30-fold during the acute phase response. Studies indicate that LBP also acts catalytically in the transfer of LPS to HDL, thus accelerating LPS detoxification. In addition, LBP and soluble CD14 can also function in phospholipid transport.

1. Hailman, E. et al. (1994) J. Exp. Med. 179:269.
2. Jack, R.S. et al. (1997) Nature 389:742.
3. Schumann, R.R. et al. (2000) Chem. Immunol. 74:42.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for LBP Antibody (AF870)(5)

Publications using AF870

• Gaspard Kerner, Anna-Lena Neehus, Quentin Philippot, Jonathan Bohlen, Darawan Rinchai, Nacim Kerrouche et al. Genetic adaptation to pathogens and increased risk of inflammatory disorders in post-Neolithic Europe Cell Genomics 2/8/2023 [PMID: 36819665]
• Gaspard Kerner, Anna-Lena Neehus, Quentin Philippot, Jonathan Bohlen, Darawan Rinchai, Nacim Kerrouche et al. Genetic adaptation to pathogens and increased risk of inflammatory disorders in post-Neolithic Europe Cell Genomics 2023-02-08 [PMID: 36819665] (Western Blot, Human)
• Katharina Schwarzkopf, Sabrina Rüschenbaum, Samarpita Barat, Chengcong Cai, Marcus M. Mücke, Daniel Fitting et al. IL‐22 and IL‐22‐Binding Protein Are Associated With Development of and Mortality From Acute‐on‐Chronic Liver Failure Hepatology Communications 2019-03-01 [PMID: 30859151]
• Kristin LM Boylan, John D Andersen, Lorraine B Anderson, LeeAnn Higgins, Amy PN Skubitz Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum Proteome Science 2010-12-01 [PMID: 20546617]
• Azuma M, Matsuo A, Fujimoto Y, Fukase K, Hazeki K, Hazeki O, Matsumoto M, Seya T Inhibition of lipid A-mediated type I interferon induction by bactericidal/permeability-increasing protein (BPI). Biochem. Biophys. Res. Commun., 2007-01-10;354(2):574-8. 2007-01-10 [PMID: 17239348] (Neutralization, Human)

Bioinformatics

• Gene Symbol: LBP
• Uniprot:
  • AAD21962()